Tenvie Therapeutics, a US based biotechnology company focused on the treatment of neurological diseases, has launched with $200 million in funding to develop small molecule therapies for neurological, cardiometabolic, and ophthalmic diseases.

The company’s research will focus on targeting inflammation, metabolic dysfunction, and lysosomal function, with key programmes including NLRP3 and SARM1 inhibitors. The investment comes from ARCH Venture Partners, F-Prime Capital, and Mubadala Capital.